Priority 11 from the Autosomal Dominant Polycystic Kidney Disease Project

UNCERTAINTY: What symptoms are associated with cyst infection in people with ADPKD, and how are cyst infections best managed (investigated and treated)? (Priority 11)
Overall ranking	11
JLA question ID	0103/11
Explanatory note	Not available for this PSP
Evidence	Marten A. Lantinga, Niek F. Casteleijn, Alix Geudens, Ruud G.L. de Sévaux, Sander van Assen, Anna M. Leliveld, Ron T. Gansevoort, Joost P.H. Drenth, on behalf of the DIPAK Consortium, Management of renal cyst infection in patients with autosomal dominant
Health Research Classification System category	Renal and urogenital

Extra information provided by this project
Original uncertainty examples	Development of an evidence-based algorithm to guide evaluation and treatment of renal cyst infection. ~ What is the value of fluorodeoxyglucose positron emission tomography (FDG-PET) and biomarkers, for people with ADPKD, to support the diagnosis and management of renal cyst infection? ~ What is the most effective route of administration and optimal duration of antibiotics for the treatment of renal cyst infection in people with ADPKD? ~ What are the indications for and value of cyst drainage for the treatment of renal cyst infection in people with ADPKD? ~ Development of diagnostic criteria for polycystic liver disease cyst infection in people with ADPKD. ~ What are the risk factors, in people with ADPKD, of polycystic liver disease cyst infection? ~ What is the optimal duration of antibiotic treatment for polycystic kidney disease cyst infection, in people with ADPKD, and what is the risk of relapse/recurrence of cyst infection? ~ How effective is penetration of the newer antibiotics into cyst fluid for the treatment of polycystic liver disease cyst infection in people with ADPKD?
Submitted by	Autosomal Dominant Polycystic Kidney Disease (ADPKD): Report from a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference (.PDF)

Extra information provided by this project

Original uncertainty examples

Development of an evidence-based algorithm to guide evaluation and treatment of renal cyst infection. ~ What is the value of fluorodeoxyglucose positron emission tomography (FDG-PET) and biomarkers, for people with ADPKD, to support the diagnosis and management of renal cyst infection? ~ What is the most effective route of administration and optimal duration of antibiotics for the treatment of renal cyst infection in people with ADPKD? ~ What are the indications for and value of cyst drainage for the treatment of renal cyst infection in people with ADPKD? ~ Development of diagnostic criteria for polycystic liver disease cyst infection in people with ADPKD. ~ What are the risk factors, in people with ADPKD, of polycystic liver disease cyst infection? ~ What is the optimal duration of antibiotic treatment for polycystic kidney disease cyst infection, in people with ADPKD, and what is the risk of relapse/recurrence of cyst infection? ~ How effective is penetration of the newer antibiotics into cyst fluid for the treatment of polycystic liver disease cyst infection in people with ADPKD?

Submitted by

Autosomal Dominant Polycystic Kidney Disease (ADPKD): Report from a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference (.PDF)

Project information
Project unique ID	0103
Project name	Autosomal Dominant Polycystic Kidney Disease
Total number of uncertainties identified by this project.	35 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop	15 December 2020